MAP Pharma updates on two Ph III programs

California, USA-based MAP Pharmaceuticals has updated investors on the progress of two current Phase III clinical programs.

Initial enrollment for a trial of the firm's Unit Dose Budesonide, for  children with asthma, completed in September 2008, and all patients have  now completed the treatment period. In the multicenter, randomized,  double-blind, placebo-controlled trial in around 360 children with  asthma, from 12 months to eight years of age, patients received either  0.25mg UDB, 0.135mg UDB or placebo twice a day over a 12-week treatment  period. The co-primary efficacy endpoints for the study are the change  in night-time and daytime composite symptom scores.

An initial trial of MAP0004 in the acute treatment of migraine, on the  other hand, is expected to complete enrollment by the end of the month.  The multicenter, randomized, double-blind, placebo-controlled trial in  approximately 850 migraine sufferers who will be evaluated for the  treatment of a single migraine is part of a special protocol assessment  with the Food and Drug Administration.